ClinVar Miner

Submissions for variant NM_000051.4(ATM):c.749G>A (p.Arg250Gln)

gnomAD frequency: 0.00007  dbSNP: rs56123940
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 17
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Ambry Genetics RCV000129173 SCV000183906 likely benign Hereditary cancer-predisposing syndrome 2018-09-29 criteria provided, single submitter clinical testing This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity.
GeneDx RCV001704053 SCV000209681 likely benign not provided 2020-10-28 criteria provided, single submitter clinical testing This variant is associated with the following publications: (PMID: 19404735, 17344846, 22529920, 28779002, 31159747)
Labcorp Genetics (formerly Invitae), Labcorp RCV000204231 SCV000259752 likely benign Ataxia-telangiectasia syndrome 2024-01-29 criteria provided, single submitter clinical testing
Counsyl RCV000204231 SCV000799869 uncertain significance Ataxia-telangiectasia syndrome 2018-05-15 criteria provided, single submitter clinical testing
GeneKor MSA RCV000129173 SCV000821872 uncertain significance Hereditary cancer-predisposing syndrome 2018-08-01 criteria provided, single submitter clinical testing
Mendelics RCV003492586 SCV000838477 likely benign Hereditary cancer 2024-01-23 criteria provided, single submitter clinical testing
Color Diagnostics, LLC DBA Color Health RCV000129173 SCV000910702 likely benign Hereditary cancer-predisposing syndrome 2015-08-05 criteria provided, single submitter clinical testing
Women's Health and Genetics/Laboratory Corporation of America, LabCorp RCV000211952 SCV001360414 likely benign not specified 2021-07-17 criteria provided, single submitter clinical testing Variant summary: ATM c.749G>A (p.Arg250Gln) results in a conservative amino acid change in the encoded protein sequence. Five of five in-silico tools predict a benign effect of the variant on protein function. The variant allele was found at a frequency of 4.8e-05 in 250992 control chromosomes in the gnomAD database, including 1 homozygote. This frequency is not significantly higher than expected for a pathogenic variant in ATM causing Ataxia-Telangiectasia (4.8e-05 vs 0.004), allowing no conclusion about variant significance. However, the presence of a homozygous occurrence in healthy controls suggests that the variant has a neutral impact. c.749G>A has been reported in the literature in settings of multigene panel testing in individuals affected with various cancer phenotypes without strong evidence for causality (examples-Grennman_2007, LaPaglia_2009, Haiman_2013, Tung_2015, Muller_2015, Tiao_2017, Martin-Moales_2018, Tsaousis_2019, Weitzel_2019, Sandoval_2021). These report(s) do not provide unequivocal conclusions about association of the variant with Ataxia-Telangiectasia. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. Nine clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation. Multiple laboratories reported the variant with conflicting assessments (likely benign, n=4; VUS, n=4). Based on the emerging majority consensus among peers and the evidence outlined above, the variant was re-classified as likely benign.
Division of Medical Genetics, University of Washington RCV001257469 SCV001434275 uncertain significance Familial cancer of breast 2019-10-04 criteria provided, single submitter clinical testing This variant has been reported in the literature in an individual with breast cancer (Paglia 2010). This variant has an overall allele frequency of 0.00005 in the Broad Institute gnomAD Browser (https://gnomad.broadinstitute.org/). In silico analyses indicate that this variant does not alter protein structure/function. Thus, it is unknown at this time whether this variant increases cancer risk. BP4
CHEO Genetics Diagnostic Laboratory, Children's Hospital of Eastern Ontario RCV001798434 SCV002042895 uncertain significance Breast and/or ovarian cancer 2019-05-24 criteria provided, single submitter clinical testing
National Health Laboratory Service, Universitas Academic Hospital and University of the Free State RCV002225424 SCV002505028 likely benign Hereditary breast ovarian cancer syndrome 2022-04-19 criteria provided, single submitter clinical testing
Sema4, Sema4 RCV000129173 SCV002538038 likely benign Hereditary cancer-predisposing syndrome 2020-12-09 criteria provided, single submitter curation
Quest Diagnostics Nichols Institute San Juan Capistrano RCV001704053 SCV002774770 uncertain significance not provided 2021-07-20 criteria provided, single submitter clinical testing
CeGaT Center for Human Genetics Tuebingen RCV001704053 SCV002821661 likely benign not provided 2022-10-01 criteria provided, single submitter clinical testing ATM: BP4, BS2
Myriad Genetics, Inc. RCV001257469 SCV005083937 likely benign Familial cancer of breast 2024-04-23 criteria provided, single submitter clinical testing This variant is considered likely benign. This variant is strongly associated with less severe personal and family histories of cancer, typical for individuals without pathogenic variants in this gene [PMID: 25085752].
Natera, Inc. RCV000204231 SCV001454847 likely benign Ataxia-telangiectasia syndrome 2020-09-16 no assertion criteria provided clinical testing
GenomeConnect, ClinGen RCV001704053 SCV002075271 not provided not provided no assertion provided phenotyping only Variant interpreted as Uncertain significance and reported on 08-11-2016 by Lab or GTR ID 26957. GenomeConnect assertions are reported exactly as they appear on the patient-provided report from the testing laboratory. GenomeConnect staff make no attempt to reinterpret the clinical significance of the variant.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.